Why the Cervical Cancer Vaccine Is So Controversial

She was 32, newly married, and ready to start a family when the call came. A California woman, who asked not to be named for privacy reasons, had just had a routine Pap smear as part of her pre-pregnancy checkup. What came back wasn’t a green light. It was an early-stage cervical cancer diagnosis tied to an HPV infection she had been carrying, unknowingly, for years.She had skipped the vaccine as a teenager: she had heard troublesome things, worried about side effects, and figured it could never happen to her.“I thought I was active and healthy and hadn’t had very many partners,” she tells the New York Sun. “I didn’t think I was the kind of person who got cancer, and especially not something sexually transmitted.”She isn’t alone. Across America, women who avoided the vaccine for human papillomavirus, known as HPV, in adolescence or early adulthood are now confronting its consequences in their 20s and 30s, often at exactly the moment they are planning pregnancies, building careers, or simply assuming that a disease their doctors could have prevented was someone else’s problem.The vaccine exists. It has existed since 2006, when the Food and Drug Administration first approved Gardasil. In the nearly two decades since, more than 160 studies and multiple international monitoring systems have found its safety profile to be consistently favorable, with no serious safety signals identified.Yet, the United States finds itself moving in the opposite direction from the rest of the world. So, why the controversy?A Gap That Keeps WideningThe numbers paint a vivid picture. Across the United States, cervical cancer incidence rates in women ages 20 to 31 fell by 27 percent during the vaccination era — comparing 2016 to 2021, when the vaccine was widely available, against 2000 to 2005, the years before it was introduced, dropping from 5.1 to 3.7 cases per 100,000.In England, girls offered the vaccine at age 12 or 13 saw cervical cancer rates fall by 87 percent relative to unvaccinated cohorts, with precancerous lesion rates dropping by as much as 97 percent.The vaccine itself was born from decades of detective work. German virologist Harald zur Hausen spent years pursuing a theory that most of his colleagues dismissed, that a sexually transmitted virus, not the herpes simplex virus as was then assumed, was the true cause of cervical cancer.In 1983, Dr. zur Hausen’s team identified HPV-16 in cervical tumor samples, followed by HPV-18 the following year — two strains now known to cause roughly 70 percent of all cervical cancers. His discovery earned him the Nobel Prize in Physiology or Medicine in 2008 and, more consequentially, paved the way for Gardasil.The mechanism is straightforward: HPV, transmitted through sexual contact, can embed itself in cervical cells and, in a fraction of persistent infections, trigger the genetic changes that turn healthy tissue into cancer. The vaccine works by priming the immune system to block that initial infection before it ever takes hold.In 1983, Mr. zur Hausen’s team identified HPV-16 and HPV-18 in cervical tumor samples, two strains now known to cause roughly 70 percent of all cervical cancers. His discovery earned him the Nobel Prize in Physiology or Medicine in 2008 and, more consequentially, paved the way for Gardasil.The mechanism is straightforward: HPV, transmitted through sexual contact, can embed itself in cervical cells and, in a fraction of persistent infections, trigger the genetic changes that turn healthy tissue into cancer. The vaccine works by priming the immune system to block that initial infection before it ever takes hold.Then there is Australia. For the first time since records began in 1982, there were no cervical cancer cases diagnosed in women under 25 in 2021, with modeling projecting the country will become the first nation to eliminate the disease entirely by 2035.Prof. Julia Brotherton, who specializes in cancer prevention policy at the University of Melbourne and has spent her career studying exactly this trajectory, tells the Sun the direction of travel is unambiguous.“There is no doubt that, with the advances in medical science we are so lucky to have access to now, cervical cancer is now a largely preventable disease,” she says. “In the long term, elimination can be sustained with vaccination alone, but only if the vaccine is completely routine and maintained at a high coverage rate. It needs to be an absolutely normal part of childhood.”Pediatrician and infectious disease specialist Dr. Paul Offit, who has spent decades studying the vaccine, is equally direct.“The notion that anybody would choose not to get it is amazing,” he tells the Sun. “It’s reduced the instance of cervical cancer deaths in this country by more than 60 percent.”That toll is not limited to women. The vaccine was recommended for girls when it was first introduced in 2006; however, it took until 2011 for ACIP to extend routine vaccination to boys at the same age — 11 or 12 — a delay Dr. Offit has long criticized.The lag mattered because HPV does not spare men. Over 14,000 men are diagnosed with HPV-caused cancers in the United States every year, with oropharyngeal cancer — cancer of the throat and tonsils- now accounting for a significant and growing share. More than 60 percent of oropharyngeal cancers are caused by HPV, according to the CDC.The issue broke into public consciousness in 2013 when actor Michael Douglas disclosed that his stage IV throat cancer was linked to HPV — a moment that doctors credited with raising awareness about a disease trend they had been watching with alarm for years.“Men account for about a third of cases,” Dr. Offit tells the Sun.A Vote That Never CameThe picture in Washington, however, looks somewhat different from the one in Melbourne or London.On June 9, 2025, Health and Human Services Secretary Robert F. Kennedy Jr. fired all 17 members of the Advisory Committee on Immunization Practices and announced their replacements two days later. The timing mattered: the old committee had been days away from a scheduled vote on HPV policy questions, including whether to broaden the age for routine vaccination. It never got to vote.The new working group’s charter, finalized in December, called for a sweeping reexamination, including adjuvant toxicity, potential contaminants, and possible HPV type replacement — going well beyond the one genuinely open question in HPV vaccine science: whether a single dose provides adequate long-term protection.Scientifically, the vaccine’s safety record is well established: the most common side effects are soreness and redness at the injection site, and more than 160 studies have found no link to serious adverse events such as autoimmune disease or neurological disorders. That has not stopped litigation.Hundreds of plaintiffs filed suit against Merck, alleging Gardasil caused conditions including postural orthostatic tachycardia syndrome and premature ovarian failure — claims Merck has vigorously denied, citing clinical trial data and global regulatory decisions.In March 2025, a federal judge dismissed the majority of those cases, ruling that the failure-to-warn claims were preempted by federal law, finding that the evidence presented, largely case reports and adverse event filings, did not meet the legal threshold required to compel a label change.In a statement, Merck said “the evidence that Gardasil does not cause POTS and its associated symptoms or POI is consistent and overwhelming,” citing data from clinical trials, real-world epidemiological studies, and global regulatory decisions. The litigation, however, has continued to fuel public doubt.Law Professor at UC Law San Francisco, Dorit Reiss, who has closely followed vaccine policy, tells the Sun the controversy is less about science than about ideology.“There are no legitimate concerns about adjuvant toxicity or contaminants,” she says. “The vaccine is one of the most well-researched we have ever had, and 20 years of global use with over 800 million doses demonstrate it is very safe and very effective.”Part of what has always complicated the HPV vaccine’s reception, Dr. Offit points out, is the discomfort that comes with the territory. Because the virus is sexually transmitted, recommending it to adolescents has never felt straightforward to everyone.“Pediatricians are talking about preventing a disease that, for the most part, they haven’t seen,” he tells the Sun. “They’re recommending a vaccine for something that happens 20 to 25 years later, and talking about sex with a young boy was more difficult for people.”Early opposition also included fears that vaccinating against a sexually transmitted infection would encourage promiscuity, a claim that was studied and found to have no basis.The new ACIP charter also grants non-voting memberships to organizations, including the Independent Medical Alliance, Physicians for Informed Consent, and the Association of American Physicians and Surgeons. These groups maintain that vaccine risks are understated.Not everyone views the restructured committee as a threat to scientific integrity. President and CEO of Children’s Health Defense, an anti-vaccine advocacy group, Mary Holland, argues the exclusion of groups like the AAP, ACOG, and IDSA may actually strengthen the process, pointing to financial ties between those organizations and Gardasil’s manufacturer. She notes that Merck has given grants to ACOG, holds Silver industry partner status with the IDSA Foundation, and sits in the President’s Circle of the AAP’s corporate supporters. “Excluding them bolsters the credibility of the group,” Ms. Holland tells the Sun. On the broader review itself, she adds that scrutiny of the vaccine’s safety record is always warranted, and that resolving questions about DNA contamination in HPV vaccines is, at minimum, necessary to fully characterize the risk.This refers to a claim that has circulated in vaccine-skeptic circles since 2011, when pathologist Dr. Sin Hang Lee reported finding fragments of HPV DNA bound to the aluminum adjuvant in Gardasil samples. His findings were formally published in the Journal of Inorganic Biochemistry in 2012. The FDA responded at the time, stating the fragments are an expected byproduct of the manufacturing process and do not pose a safety risk — a position subsequently endorsed by regulators in Australia and other countries. Vaccine-skeptic advocates, however, contend that the issue was never adequately investigated.One Dose, No vote, and a Financial QuestionEarlier this year, the administration moved further from pushing the HPV vaccine. On January 5, the CDC announced a sweeping revision to the childhood immunization schedule, reducing the number of recommended vaccines from 17 to 11 diseases. As part of that overhaul, the agency moved to a single-dose HPV recommendation, a change imposed without an ACIP vote.Longitudinal studies have shown that one dose is as effective as two, and the United States now joins more than 80 countries, including the United Kingdom, Canada, and Australia, in adopting a single-dose regimen. However, because the CDC imposed the one-dose change without an ACIP vote, it became part of a broader legal challenge, and in March this year, United States District Judge Brian E. Murphy temporarily blocked the revised schedule entirely. Insurance coverage obligations have reverted accordingly, though the litigation is ongoing and the outcome uncertain. Major insurers, at least for now, have confirmed they will continue covering all vaccines recommended under the pre-2025 schedule through at least the end of 2027 while the litigation proceeds. However, what makes this so contentious in America, while the rest of the world has moved toward elimination, is a collision of culture, politics, and money that has no equivalent elsewhere. The advisory process was bypassed. The committee that would have voted was disbanded. In March, a federal judge ruled that Secretary Kennedy’s reconstitution of the ACIP likely violated the Federal Advisory Committee Act — finding that of the 13 members he appointed, only six appeared to have any meaningful expertise in vaccines, and issued a preliminary injunction blocking the committee from meeting and invalidating all votes it had taken. Dr. Offit frames what is at stake in terms of medicine that is rarely used.“It’s the only known cause of cervical cancer,” he says. “The vaccine is safe, and it’s effective — and a disease that medicine genuinely knows how to stop, we appear to be stepping back from stopping.”HHS has signaled it may reconstitute the committee again to work around the ruling. The government has since filed an appeal to the First Circuit. Vaccine supporters stress that, for the women who will be diagnosed in the years ahead, the distance between political controversy and medical reality is not abstract.“Anyone who has personally witnessed the absolutely devastating impact of cervical cancer on women, their families and communities will understand just how critical this vaccine is,” Ms. Brotherton adds. “Any review that undermines the strong public health recommendation for routine use of the HPV vaccine would be simply shameful and completely out of step with the global evidence supporting this remarkable vaccine.”

Why the Cervical Cancer Vaccine Is So Controversial

More from the New York Sun

Electricity Prices Have Surged 18 Percent Since Trump Took Office Despite His Promise to Cut Them in Half

The New 5-A-Day? Heart Docs Say Up to Five Coffees Is Fine

As War Intensifies, Iran Steels the Houthis, Hezbollah, and Hamas

More from the New York Sun

Electricity Prices Have Surged 18 Percent Since Trump Took Office Despite His Promise to Cut Them in Half

The New 5-A-Day? Heart Docs Say Up to Five Coffees Is Fine

As War Intensifies, Iran Steels the Houthis, Hezbollah, and Hamas

A Legal Victory for ‘America’s Rifle’

Date Set for Trump’s Bid To Resurrect Troubled Prosecutions Against James Comey and Letitia James

Britain’s New Prime Minister Promises the Panacea of a ‘Ten-Year Plan’ That Would Move the Country to the Left

FDA Says False-Positive Test Doesn’t Clear Taylor Farms Lettuce as Source of Cyclospora Outbreak

Federal Judge Temporarily Blocks Paramount-Warner Bros. Merger